Abstract-Several phosphorylation signaling pathways have been implicated in the pathogenesis of epilepsy arising from both genetic causes and acquired insults to the brain. Identification of dysfunctional signaling pathways in epilepsy may provide novel targets for antiepileptic therapies. We previously described a deficit in phosphorylation signaling mediated by p38 mitogen-activated protein kinase (p38 MAPK) that occurs in an animal model of temporal lobe epilepsy, and that produces neuronal hyperexcitability measured in vitro. We asked whether in vivo pharmacological manipulation of p38 MAPK activity would influence seizure frequency in chronically epileptic animals. Administration of a p38 MAPK inhibitor, SB203580, markedly worsened spontaneous seizure frequency, consistent with prior in vitro results. However, anisomycin, a non-specific p38 MAPK activator, significantly increased seizure frequency. We hypothesized that this unexpected result was due to activation of a related MAPK, c-Jun N-terminal kinase (JNK). Administration of JNK inhibitor SP600125 significantly decreased seizure frequency in a dose-dependent manner without causing overt behavioral abnormalities. Biochemical analysis showed increased JNK expression and activity in untreated epileptic animals. These results show for the first time that JNK is hyperactivated in an animal model of epilepsy, and that phosphorylation signaling mediated by JNK may represent a novel antiepileptic target.
INTRODUCTION
Much attention has been devoted to the causes underlying the development of epilepsy following an acquired insult to the brain. One leading hypothesis suggests that the development of ion channel dysfunction or ''acquired channelopathy" leads to neuronal hyperexcitability and seizures. Dysfunction of numerous species of voltage-gated ion channels, such as the K + channel Kv4.2 and the Ca 2+ channel Cav3.2, and ligand-gated channels such as GABA A receptors and AMPA receptors, has been documented in animal models of acquired epilepsy; all of these promote neuronal hyperexcitability (Jacob et al., 2008; Rakhade et al., 2012; Poolos and Johnston, 2012) . In studying the relationship of hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel dysfunction and epilepsy, we and others have found downregulation of HCN channel expression following status epilepticus (SE) provoked by chemoconvulsants that precedes the development of epilepsy (Shah et al., 2004; Jung et al., 2007 Jung et al., , 2011 Williams et al., 2015) . However, in chronic epilepsy, downregulation of HCN channel voltagedependent activation also occurs, and additionally promotes neuronal hyperexcitability. This gating defect in HCN channel function depended on loss of activity of an upstream signaling cascade mediated by p38 mitogenactivated protein kinase (p38 MAPK), and increased activity of protein phosphatase 2B (Jung et al., 2010) . These two biochemical alterations produced a net loss of phosphorylation in hippocampal tissue. hippocampal pyramidal neurons from epileptic animals were studied in vitro, pharmacological reversal of these signaling abnormalities restored neuronal excitability to normal. We therefore hypothesized that pharmacological manipulation of the p38 MAPK pathway in vivo might influence seizure frequency in chronically epileptic rats.
Phosphorylation signaling pathways like p38 MAPK are ubiquitous regulators of cellular function. Pharmacological modulation of phosphorylation signaling is increasingly recognized as an important therapeutic area (Cohen, 2002; Chico et al., 2009) . In epilepsy, the numerous ion channelopathies set into motion by a brain insult likely reflect the diverse action of upstream signaling processes; thus it could be advantageous to identify and pharmacologically manipulate those signaling pathways rather than individual ion channels, their downstream targets. Conventional antiepileptic drug (AED) development-mostly focused on voltage-and ligand-gated ion channels-has made disappointingly little progress over recent decades in treating that onethird of all epilepsy patients who are refractory to medical therapy (Loscher and Schmidt, 2011) . Thus, there is a compelling need to understand the root causes of the initiation and maintenance of the epileptic state, and to identify novel therapies.
In this study, we used the pilocarpine animal model of epilepsy to study the effect of pharmacologically manipulating MAPK signaling. We chose to study modulation of kinase rather than phosphatase signaling due to the presumably more diverse downstream effects of manipulating phosphatase activity. We first validated that inhibition of p38 MAPK activity in vivo exacerbated spontaneous seizure frequency in chronically epileptic animals. We then fortuitously discovered that inhibition of a related MAPK, c-Jun N-terminal kinase (JNK), reduced seizure frequency. Biochemical analysis of hippocampal tissue from epileptic animals showed chronic elevation of JNK activity. The finding of JNK hyperactivation in an animal model of epilepsy may mark it as a novel therapeutic target in human refractory epilepsy.
EXPERIMENTAL PROCEDURES Pilocarpine model of epilepsy
We generated chronically epileptic animals using the pilocarpine protocol as previously described (Jung et al., 2007) . The University of Washington Institutional Animal Care and Use Committee approved all animal procedures. In brief, 6-week-old male Sprague-Dawley rats underwent induction of SE with pilocarpine hydrochloride (385 mg/kg intraperitoneal [i.p.]) after pretreatment with scopolamine methylnitrate (1 mg/kg i.p.). After 60 min of convulsive SE, seizures were terminated with repeated doses of diazepam (12 mg/kg i.p.) or phenobarbital (PB; 15 mg/kg i.p.) every 30-45 min until cessation of convulsive motor activity. In cohorts of chronically epileptic animals evaluated at 6 weeks post-SE, average baseline seizure frequency ranged from 1.6 to 4.3 convulsive seizures per day. Baseline seizure frequency was lower (0.88 seizures per day) in one cohort of animals that received more frequent post-SE dosing of PB (at 20-30 min intervals) in an attempt to reduce post-SE mortality.
Surgical protocol and video-EEG recording
Five weeks post-SE, animals were implanted with epidural electroencephalogram (EEG) electrodes according to a modification of our previous published protocol (Jung et al., 2007) . We implanted two electrodes positioned over the right and left parietal convexities, plus a reference electrode approximately 2 mm anterior and to the right of bregma. We also placed an intracerebroventricular (i.c.v.) cannula (DURECT Corp., Cupertino, CA) into the right lateral ventricle (at position AP = À1.2; ML = 2.2). Epidural electrodes, cannula, and a cable pedestal were secured with dental acrylic. A subcutaneous pocket was then created over the dorsal thorax, and an osmotic pump (Alzet 2ML2 or 2ML4; DURECT Corp.) containing vehicle solution was inserted and connected via polyethylene tubing to the cannula. Following closure of the incision, animals were given buprenorphine (0.10 mg/kg; Bedford Laboratories, Bedford, OH) to minimize discomfort.
Animals underwent baseline video-EEG recordings after a one-week post-surgery recovery period. Their headsets were attached to a wire cable, and they were placed in individual acrylic cages. EEG signals were amplified with a Grass Model 8-10 D amplifier (Grass Tech., West Warwick, RI) and acquired using a PowerLab 8/30 module equipped with Chart Pro software (AD Instruments, Colorado Springs, CO). Video recording utilized a ZR500 digital camcorder (Canon, Lake Success, NY), which interfaced with the Chart software, allowing for synchronization of the video and EEG traces. During baseline and drug treatment phases, animals underwent continuous 24/7 video-EEG recording for an average of 10 d during each phase. Seizures were classified by visual inspection of the video-EEG records according to the Racine scale, with event severity ranging from class 1 (C1) to class 5 (C5) (Racine, 1972) . Although all classes of seizure were recorded, only C3-5 seizures (which were the predominant classes) were used for measurement of seizure frequency. Seizure duration was measured as the time between electrographic onset and offset. After baseline video-EEG recording, animals underwent a brief surgical procedure to replace the vehicle osmotic pump with drug-containing solution. After a three-day recovery period, a repeat video-EEG recording session occurred during drug delivery. Fig. 1A shows our experimental protocol, in which monitoring during baseline and drug treatment occurred during weeks 6-9 post-SE. An important advantage of this protocol is that within-subject comparisons of baseline and drug treatment phases normalize for the inherent variability in seizure frequency among pilocarpine-treated animals. Thus each animal served as its own control. Also, i.c.v. delivery of drugs via osmotic pump achieves steady-state drug levels without diurnal variation; avoids issues with drug blood-brain barrier permeability; avoids the animal stress that would occur with repeated drug injection or gavage; and minimizes drug amounts used.
Drug delivery
All drugs were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. SB203580 was dissolved in sterile 150 mM NaCl solution plus 1% DMSO to yield 0.5 mM solution. This solution was loaded into Alzet 2ML2 pumps that deliver at 5 ll/hr to achieve a predicted steady-state cerebrospinal fluid (CSF) concentration of 20 lM (with DMSO concentration of 0.03%), based on rat CSF volume of 400 ll and turnover rate of 2.2 ll/min (3.2 ml/d; Davson et al., 1987) . We determined in ex vivo trials that drugcontaining fluid would transit the tubing connecting the osmotic pump to the i.c.v. cannula within 24 h, and thus estimated the drug should be at steady-state CSF concentration well within the 72 h between pump changes and repeat video-EEG monitoring. Anisomycin was dissolved in saline plus 1% DMSO to yield 1.1 mM solution, and was predicted to yield a steady-state CSF concentration of 40 lM. SP600125 was dissolved in saline plus 1% DMSO to yield either 0.9 or 1.8 mM solution, and was predicted to yield a steadystate CSF concentration of 20 or 40 lM, respectively. Vehicle solution consisted of saline and was delivered by either 2ML2 or 2ML4 pumps (2.5 ll/hr delivery rate). Lamotrigine isethionate (GlaxoSmithKline, Research Triangle Park, NC) was dissolved in saline at a concentration to deliver 20 mg/kg/d, loaded into 2ML4 pumps, and implanted subcutaneously over the dorsal thorax to deliver drug subcutaneously.
Open field behavioral testing
The animal was placed in a 1 m 2 square enclosure composed of 25-cm tall black Plexiglas walls with a non-reflective, rubberized floor. The center was defined as the central 50 Â 50 cm zone and each corner was defined as a 25 Â 25 cm zone. Behavior was monitored by video under dim light illumination for 10 min. Position in the field was measured by motion detection software (ANY-Maze, Stoelting Co., Wood Dale, IL), and anxiety-like behavior was quantified by the amount of time spent in the center of the field compared to the corners, with increased anxiety correlating with decreased time in the center of the field. Additional measures of motor activity, such as locomotion speed and time spent mobile were also extracted. Adult animals underwent pilocarpine induction and then were implanted with epidural EEG electrodes and an i.c.v. cannula connected to a vehicle pump at week 5 post-SE. A 10-day continuous baseline video-EEG monitoring period began at week 6, followed by a change to a drug-containing pump, and repeat 10-day monitoring. Following this monitoring period, the animals were sacrificed. (B) EEG tracing during a typical Racine class 5 seizure. Shown are right (R) and left (L) epidural cortical electrode channels, with behavioral changes and Racine classifications noted during the course of the electrographic seizure. The typical convulsive seizure in this model is readily apparent from the onset of a high-amplitude, high-frequency electrographic discharge that gradually increases in amplitude followed by a waning phase. (C) Seizure frequency in animals treated throughout weeks 6-9 with a saline pump. Traces show average C3-5 seizure frequency during the two 14-day periods for six animals. Animals with increased seizure frequency are depicted with solid traces; those with decreased seizure frequency with dashed traces. There was variability in the baseline seizure frequency, but little change in seizure frequency in individual animals between weeks 6-7 and 8-9. (D) Distribution of Racine classifications and seizure durations for all seizures recorded as shown in Fig. 1C . C3-5 seizures with major motor manifestations (C3-4) or convulsions (C5) were the predominant seizure types. The median seizure duration was 50 s.
Biochemistry
Animals were sacrificed with ketamine/xylazine anesthesia (87/13 mg/kg i.p.), followed by decapitation and harvest of bilateral CA1 hippocampal tissue. In each experiment, we pooled 6-8 hippocampal slices from a single animal. The CA1 regions were microdissected on dry ice and homogenized in solution containing (in mM): 4 para-nitrophenylphosphate, 1 sodium orthovanadate, 1 phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor mixture (1 tab per 10 ml; Roche, Indianapolis, IN). Homogenates were centrifuged at 15,000g for 40 min at 4°C. The pellet was then resuspended with sonication in homogenization solution then run in Lae¨mmli buffer (with final concentration of 4.5% sodium dodecyl sulfate [SDS]) on a 10% acrylamide gel, transferred to a nitrocellulose membrane, and incubated with the appropriate primary antibody, followed by incubation in secondary antibody, and visualized by enhanced chemiluminescence and film exposure. Three different protein loading amounts were used in each condition so to verify that signal detection was in the linear range, as described previously (Jung et al., 2010) . The membrane was then reprobed using anti-b-tubulin III antibody as a marker for neuronal protein content (1:20,000; SigmaAldrich) so to verify that protein loading was correct in each experiment. Test and control conditions were always analyzed within the same gel, with results reported as a percentage of control values. All antibodies were used at 1:1000 titers and were purchased from Cell Signaling Technology (Danvers, MA). Antibodies for phospho-JNK recognized phosphorylation at Thr183/Tyr185; and for phospho-c-Jun at Ser63.
Statistics
Seizure data were analyzed by calculating within-subject ratios of seizure frequency under control and drug conditions. These data were then log-transformed, and two-tailed t-tests calculated, followed by backtransformation of the mean and 95% confidence intervals (CIs). This method, used in analyses of both human and animal antiepileptic drug studies, provides a robust means of assessing drug effects in within-subject comparisons: calculation of seizure frequency ratios normalizes for the variability in baseline seizure frequency among subjects, while log-transformation produces normally distributed data that can be analyzed with parametric statistics (Eastman et al., 2010; . For comparison purposes, we also report group average data for control and drug-treated animals. The remaining statistics are reported as means ± SEM, with significance determined by two-tailed t-tests unless otherwise mentioned.
RESULTS

Seizure characteristics in the pilocarpine model
To investigate the effects of p38 MAPK signaling modulation on seizure frequency, we used the pilocarpine model (Turski et al., 1983) . This model has several benefits for the study of AED efficacy. First, animals display complex partial and secondarily generalized convulsive seizures that are prolonged and behaviorally obvious to an observer. Seizures predominately begin in the hippocampus then spread to extratemporal areas, as occurs in human temporal lobe epilepsy (Toyoda et al., 2013) . These are accompanied by electrographic discharges that when recorded from epidural electrodes are easily detected. An EEG recording of a typical Racine class 5 (C5) convulsive seizure is shown in Fig. 1B . Here, an electrographic discharge recorded from right and left parietal cortical epidural electrodes had its onset several seconds before the first behavioral change, in this case arousal from sleep. The discharge gradually gained in amplitude, accompanied by forelimb clonus (C3), followed by forelimb clonus with rearing (C4), and loss of posture with generalized convulsion (C5). As the electrographic discharge waned, the animal became motionless, followed shortly by exploring behavior. Because of these easily identified electrographic and behavioral changes, in this study we were able to rapidly review seizure occurrences in 24 h/d video-EEG monitoring over prolonged 7-10 d epochs. The obvious nature of the behavioral and electrographic changes with C3-5 seizures meant that their detection was not appreciably subject to observer interpretation, and in our experience inter-observer reliability was very high. In total, our data for this study comprised 20,867 animal-hours (869 animal-days) of video-EEG recordings.
To validate that seizure frequency is stable in our animal model during the period of evaluation, weeks 6-9 post-SE, we implanted epileptic animals with salinefilled osmotic pumps and measured spontaneous seizures over two 14-day periods, weeks 6-7, and weeks 8-9 post-SE. As seen in Fig. 1C , baseline average seizure frequency in weeks 6-7 clustered between 1 and 3 seizures per 24-h day in the majority of animals, but with one animal exhibiting a baseline of 11 seizures per day. Of the six animals, three showed modest decreases in seizure frequency in weeks 8-9, while three showed modest increases. The average change in seizure frequency in weeks 8-9 compared to weeks 6-7 for all animals was a 4.8% decrease, which was not statistically significant. These data demonstrate that while there was significant variability in baseline seizure frequency, there was little change in withinanimal comparisons of seizure frequency during the evaluation period. We also quantified the Racine class of the spontaneous seizures observed, which demonstrated a predominance of C3-5 seizures, with a median duration of 50 s (range 15-180 s; Fig. 1D ), and only rare C1-2 seizures. Because C1-2 seizures were behaviorally subtle and infrequent, we chose to quantify only C3-5 seizures for this study.
p38 MAPK inhibition worsens spontaneous seizure frequency
We first asked whether pharmacologic modulation of p38 MAPK activity would influence seizure frequency. Our previous work had shown that p38 MAPK activity is reduced in chronic epilepsy. For our initial experiments we chose to further inhibit p38 MAPK pharmacologically owing to the availability of a widely used specific inhibitor, SB203580 (SB; Martin and Arthur, 2012) . We hypothesized that p38 MAPK inhibition should increase spontaneous seizure frequency. We delivered SB at 12 lg/d i.c.v. to yield an estimated steady-state CSF concentration of 20 lM.
Inhibition of p38 MAPK with SB markedly increased seizure frequency. As shown in Fig. 2A , eight out of nine animals experienced an increase in C3-5 seizure frequency. The average group baseline seizure frequency under control conditions was 1.6 seizures/d; in the presence of SB, seizure frequency was 3.3 seizures/d. Calculated as within-subject ratios of seizure frequency under drug and control conditions followed by log transformation of the ratio data (as described in Methods), SB treatment increased seizure frequency by 164% (95% CIs [118%, 229%]; n = 9; p < 0.01). The mean Racine class for the group under control conditions was 4.3 (±0.09, n = 124) while during SB treatment was 4.2 (±0.07, n = 245); the within-subject increase in mean Racine class with SB treatment was 0.07 (±0.25, n = 9, p > 0.05), and was not statistically significant. Similarly, mean seizure duration for the cohort under control conditions was 53 s (±2.3 s, n = 108), while in SB was 43 s (±1.3 s, n = 220). However, within-subject comparisons showed a mean 5.9 s (±2.3 s, n = 9, p > 0.05) decrease in seizure duration with SB treatment that was not significant. A histogram of seizure durations in the two groups is shown in Fig. 2B .
These results obtained with in vivo p38 MAPK inhibition validated our initial hypothesis based on prior in vitro work that showed p38 MAPK inhibition significantly increases hippocampal pyramidal neuron excitability, in part via downregulation of HCN channel gating (Poolos et al., 2006; Jung et al., 2010) . We then asked whether activation of p38 MAPK might conversely decrease seizure frequency. However, there are no known selective pharmacologic activators of p38 MAPK. Anisomycin (ANI) is a non-specific activator of both p38 MAPK and the related stress-activated kinase JNK (Rosser et al., 2004) . ANI also acts to inhibit protein synthesis at 10-fold higher concentrations than those that produce activation of stress kinases (Iordanov et al., 1997) . Since there were no published reports on the effects of ANI on seizures in chronically epileptic animals, we proceeded with an experiment to deliver ANI in vivo to our pilocarpine-induced animals.
Anisomycin unexpectedly exacerbates spontaneous seizure frequency
Contrary to our prediction, anisomycin administration at 19 lg/d i.c.v. to yield an estimated steady-state CSF concentration of 40 lM, produced a significant increase in C3-5 seizure frequency (Fig. 3A) . All four ANI-treated animals showed an increase in seizure frequency; one animal with a high baseline seizure rate entered into SE within two days of change to an ANI-containing pump, ultimately resulting in near-continuous seizures before euthanization. The other three animals showed more moderate increases in seizure frequency. On average, the ANI cohort had 3.5 seizures/d at baseline, and 12.4 seizures/d with ANI treatment. The mean seizure frequency ratio of treated to control was 256% ([135%, 485%], n = 4, p < 0.05). Seizure Racine class for the group under control conditions was 4.2 (±0.06, n = 111), while during ANI administration was 3.5 (±0.08, n = 1820); in within-subject comparisons, the mean decrease in Racine class was not significant (0.17 ± 0.28, n = 4, p > 0.05). Seizure duration for the cohort under control conditions was 44 s (±0.69 s, n = 108), and following ANI 57 s (±2.5 s, n = 134). This apparent increase was driven mostly by a single subject in SE; in within-subject comparisons the mean increase in seizure duration was 24 s (±13 s, n = 4, p > 0.05), and was not significant (Fig. 3B) . Because of the consistent effect of ANI in exacerbating seizure frequency, and the occurrence of provoked SE, we terminated this experiment after exposure of just four animals.
JNK inhibition produces an antiepileptic action
The exacerbation of seizure frequency by ANI was unexpected since p38 MAPK inhibition by SB203580 had resulted in significant worsening of seizure frequency, and ANI is a potent p38 MAPK activator. However, ANI also activates related stress-activated kinase JNK (as well as inhibits protein synthesis). There had been no previous reports that modulation of JNK activity affects spontaneous seizure frequency, or that JNK is activated in chronic epilepsy. However, JNK knockout mice have reduced intensity of seizures acutely provoked by kainic acid (Brecht et al., 2005) , thus we hypothesized that pharmacologic inhibition of JNK might have an antiepileptic effect. We administered the selective JNK inhibitor SP600125 to chronically epileptic rats (Martin and Arthur, 2012) . To determine the maximal JNK inhibition that might be achieved with a concentration of SP that could be reasonably delivered via osmotic pump, we applied SP at 40 lM to hippocampal slices from naive animals incubated in vitro for one hour at 32°C. (Of note, 10 lM SP applied in vitro to cultured cells produced approximately 50% inhibition of JNK activity; Vogel et al., 2009 ). We measured phosphorylation of the canonical target of JNK, c-Jun, using a phosphospecific antibody that recognizes phosphorylation at Ser63 by all JNK isoforms. SP applied at 40 lM to hippocampal slices reduced the ratio of phosphorylated c-Jun to total c-Jun to only 55% of control (±8.1%, n = 3, p < 0.05; data not shown). Thus we concluded that SP delivered to hippocampal tissue at the maximal concentration accommodated by our osmotic pumps produces only partial inhibition of JNK activity, possibly due to poor tissue penetration of the drug. Nonetheless, we proceeded to test the efficacy of partial JNK inhibition with SP at two dosage levels.
JNK inhibition produced an antiepileptic effect. SP delivered at 14 lg/d (predicted to yield 20 lM CSF concentration) reduced the group seizure frequency to 0.59 seizures per day (±0.09, n = 7). Six of seven treated animals demonstrated decreases in seizure frequency, as shown in Fig. 4A . In the generation of this cohort of chronically epileptic animals, more aggressive phenobarbital treatment was used in an attempt to improve mortality, but unexpectedly the resulting average baseline seizure frequency was 0.88 per day (±0.09, n = 7), less than in the other cohorts. However, the mean seizure frequency ratio of treated to control was significantly reduced to 66% ([45%, 96%], n = 7, p < 0.05). JNK inhibition also produced a small decrease in seizure duration: in the control group mean duration was 43 s (±0.97 s, n = 64) while the group treated with SP 14 lg/d had a mean duration of 41 s (±1.0 s, n = 38).
Within-subject comparisons showed a small but significant mean decrease of 2.1 s (±1.0 s, n = 7, p < 0.05); Fig. 4B . Racine class was not significantly different with a mean of 4.1 (± 0.09, n = 64) in the control group and 4.3 (±0.11, n = 38) in the SP-treated group, and a within-subjects increase of 0.26 (±0.27, n = 7, p > 0.05).
In order to determine whether a positive doseresponse relationship existed for JNK inhibition and seizure frequency, we delivered SP at 28 lg/d i.c.v. (predicted to achieve steady-state 40 lM CSF concentration) to a second cohort of epileptic animals. SP at 28 lg/d produced an increased antiepileptic effect compared to SP at 14 lg/d. As shown in Fig. 4C , all seven animals exposed to SP had decreased convulsive seizure frequency. Average baseline seizure frequency of this cohort was 4.3 seizures per day (±1.7, n = 7), while after SP treatment the group seizure frequency was 1.5 seizures per day (±0.51). The mean seizure frequency ratio of treated to control was 43% ([27%, 71%], n = 7, p < 0.01). JNK inhibition in this cohort produced a similar small change in seizure duration (control: 31 ± 0.82 s, n = 262; SP 28 lg/d: 30 ± 1.0 s, n = 82) that in within-subjects comparisons was not statistically significant (mean decrease 2.0 ± 3.8 s, n = 7, p > 0.05). These results demonstrated that JNK inhibition by SP produced a dose-dependent reduction in seizure frequency, even with only partial inhibition of JNK activity.
As a comparison for the antiepileptic effect of JNK inhibition, we treated a cohort of chronically epileptic animals with the AED lamotrigine (LTG). LTG is a commonly used antiepileptic drug, with a well-defined human therapeutic concentration range of 2-20 lg/ml (Shorvon, 2000) . LTG isethionate was delivered subcutaneously via osmotic pump instead of i.c.v. because of its well-characterized efficacy when systemically administered. We first treated a pilot series of animals with LTG 20 mg/kg/d and measured serum LTG levels at three time points post-implantation of drug-filled osmotic pumps. At 3 d post-implant, the mean LTG level was 8.8 ± 1.5 lg/ml; at 7 d it was 10.6 ± 0.6; and at 10 d it was 10.4 ± 1.1 (all n = 3). Seven days post-pump removal, LTG levels were undetectable (all <0.5). Thus, within three days of LTG pump implantation, serum levels corresponding to the middle of the human therapeutic range were stably attained. We then administered LTG 20 mg/kg/d to epileptic animals. The average baseline convulsive seizure frequency in this cohort was 4.0 (±1.1, n = 11) seizures/d. Average seizure frequency during LTG treatment was 1.2 seizures/d (±0.43, n = 11). The ratio of seizure frequency in within-animal comparisons of LTG to control was 26% ([7.3%, 94%], n = 11, p < 0.05). This provides a point of comparison with the efficacy of a standard AED, and demonstrates that partial JNK inhibition has a similar antiepileptic effect as LTG dosed to achieve mid-therapeutic levels. A graphical comparison of the results from all five treatment groups is shown in Fig. 5 .
JNK inhibition does not produce behavioral abnormalities
We then asked whether JNK inhibition at the higher SP dose was associated with toxicity manifested by behavioral abnormalities. To test for abnormal locomotion and also for any effects on anxiety-like behavior, we performed open-field testing on epileptic animals treated with SP 28 lg/d; untreated, age-matched epileptic animals; and naive, age-matched controls. Prior studies have shown that increased anxiety-like behavior is a comorbidity of epilepsy induced in mice with pilocarpine or kainic acid (Muller et al., 2009; Liu et al., 2013) , while decreased anxiety-like behavior is seen in pilocarpine-induced rats (Detour et al., 2005; Cardoso et al., 2009; Inostroza et al., 2012) . As shown in Fig. 6A , SP treatment did not alter mean locomotion speed or the amount of time spent mobile, showing that JNK inhibition did not produce gross motor impairment or lethargy. The untreated epileptic group showed decreased anxiety-like behavior compared to naive controls, as manifested by increased amounts of time spent exploring in the center area of the field (epileptic: 77.5 ± 14.3 s, n = 11; naive: 34.0 ± 6.5 s, n = 9, p < 0.05 by a one-way ANOVA with the Tukey post-hoc test; Fig. 6B ). There were no significant differences in anxiety-like behavior between SP treated and untreated epileptic animals. The decrease in anxiety-like behavior in our epileptic animals is consistent with several prior studies in rats, while mice show increases in anxiety-like behavior; thus it appears that behavioral alterations in post-SE epilepsy models animals have speciesdependent differences. Regardless, these results also show that JNK inhibition did not overtly affect behavior in our animals.
Elevated JNK signaling in chronic epilepsy
Since JNK inhibition produced an antiepileptic effect, we asked whether our chronically epileptic animals showed evidence of increased JNK expression or activation. We harvested hippocampal tissue from a cohort of untreated, chronically epileptic animals at 6 weeks post-SE, and used pan-specific antibodies to measure total and phosphorylated JNK protein expression. JNK isoforms tend to segregate electrophoretically in two main bands: isoforms JNK1 and JNK3 run in a 46-kDa band (which sometimes shows an additional weak band at a slightly higher mobility), and JNK2 in a 54-kDa band (Brecht et al., 2005) . We quantified the aggregate expression of all three isoforms together. As a positive control for detection of JNK activation, we first measured JNK expression in hippocampal tissue harvested from naive animals and exposed in vitro to 20 lM anisomycin for 60 min, which produces substantial activation of JNK signaling. Phosphorylated JNK (pJNK) levels in ANI-treated tissue were 162% (±8.0%, n = 5, p < 0.01; Fig. 7A ) of control, with a no significant change in total JNK expression (117 ± 6.8%, n = 5, p > 0.05), yielding an increase in pJNK/-total JNK ratio of 139% (±5.4%, n = 5, p < 0.01). This validated our ability to detect JNK activation by a known positive modulator.
We then assayed JNK activation in epilepsy. Chronically epileptic animals showed elevated levels of activated pJNK at 144% of those in naive, nonepileptic controls (±17%, n = 7, p < 0.05), with a mean phospho-to total JNK ratio of 139 ± 7.7% (n = 7, p < 0.01). There was a modest increase in total JNK protein expression (120 ± 5.6% of control, n = 7, p < 0.05, Fig. 7B ) compared to naive controls as well. These results demonstrate that JNK signaling is hyperactivated in hippocampal tissue from chronically epileptic animals, with the degree of JNK hyperactivation seen in epileptic tissue a significant fraction of that seen with stimulation of JNK activity by ANI in naive tissue.
We next determined whether activated JNK produced downstream phosphorylation of its canonical target, c-Jun. We first validated that activation of JNK by ANI in (B) Untreated epileptic animals showed decreased anxiety-like behavior as shown by increased time spent in the center of the field, compared to naive controls. There were no differences in these measures between treated and untreated epileptic animals.
naive tissue in vitro produced c-Jun phosphorylation. As shown in Fig. 7C , ANI produced a marked elevation of the fraction of phosphorylated c-Jun (pc-Jun/total c-Jun) to 227% of control (±15.3%, n = 4, p < 0.01), demonstrating that JNK activation had functional downstream effects on the phosphorylation of c-Jun, as expected. Interestingly, total c-Jun protein expression declined to 54% of control (±9.4%, p < 0.05), leaving the total amount of pc-Jun unchanged by ANI activation (120 ± 16.7% of control, p > 0.05). The mechanism underlying the acute decline of c-Jun expression is unclear, but this phenomenon has been observed previously following stimulation by ANI (Leppa et al., 1998; Morton et al., 2003) . We then measured c-Jun phosphorylation in tissue from chronically epileptic animals (Fig. 7D) . Similar to the effect seen with in vitro stimulation by ANI, the fraction of phosphorylated pc-Jun to total c-Jun was elevated at 157% of naive, nonepileptic controls (±10.1%, n = 5, p < 0.01). Likewise, the expression level of total c-Jun was decreased to 65% of control (±5.6%, p < 0.01), leaving total pc-Jun expression unchanged from control (110 ± 5.6%, p > 0.05).
The level of pc-Jun activation in epilepsy was concordant with the level of JNK activation, and demonstrates that activated JNK has functional downstream signaling actions in chronic epilepsy.
DISCUSSION
In this study we translated a prior finding, that loss of p38 MAPK signaling in chronic epilepsy contributes to neuronal hyperexcitability, to an in vivo trial of pharmacologic MAPK modulation in order to test its effect on spontaneous seizure frequency in chronically epileptic animals. We employed the pilocarpine model of temporal lobe epilepsy, with prolonged 10-d periods of video-EEG monitoring during both baseline and treatment phases in within-subject comparisons, as a rigorous test of antiepileptic efficacy against spontaneous seizures. We found that inhibition of brain p38 MAPK activity produced a significant increase in seizure frequency, validating the role of this signaling pathway role in modulating seizure activity. Following an unexpected result from treatment with the non-specific MAPK activator anisomycin, we determined that partial inhibition of JNK activity produced a substantial, dosedependent antiepileptic effect without causing overt behavioral abnormalities. Finding elevated JNK expression and activity in chronically epileptic animals supported the idea that JNK hyperactivation may be relevant to the pathogenesis of chronic epilepsy. These results represent the novel identification of JNK phosphorylation signaling as a potential antiepileptic target in temporal lobe epilepsy.
JNK inhibition produces an antiepileptic action
We demonstrated a significant reduction of spontaneous seizure frequency with inhibition of JNK activity by SP600125. Using two SP dosages, we observed a positive dose-response relationship, with the lower dose producing a 34% reduction of convulsive seizure frequency, while a twofold higher dose produced a 57% reduction. In both cases, it is likely that only partial inhibition of JNK signaling was achieved. This may reflect poor tissue penetration of the drug, as even in vitro application of 40 lM SP to brain slices, a concentration that is four times the IC50 seen with application to cultured cells (Vogel et al., 2009) , yielded only about 50% inhibition of JNK activity. Nonetheless, even partial JNK inhibition produced a significant antiepileptic effect. We included the lamotrigine data as a comparator for the antiepileptic effect of JNK inhibition. Since lamotrigine is a clinically validated antiepileptic drug active at a known concentration range (which we achieved in our study), the LTG data show that partial JNK inhibition achieved a comparable magnitude of seizure frequency reduction as LTG dosed in the middle of the human therapeutic range. (However, there is no reason to suspect that LTG's mechanism of action depends on MAPKs.) This raises the possibility that with more complete inhibition of JNK activity, a more substantial antiepileptic effect might be achieved. JNK inhibition at the higher dose did not produce behavioral abnormalities in tests of open-field locomotion.
Prior studies of the association between JNK and epilepsy have demonstrated acute increases in JNK activation following chemoconvulsant-induced SE or kindling (Mielke et al., 1999; Schauwecker, 2000; Jeon et al., 2000; Cole-Edwards et al., 2006) . Knockout of the JNK3 isoform diminished the seizure class acutely provoked by kainate administration (Brecht et al., 2005) , while knockdown of JNK-interacting protein (JIP3) decreased JNK activation and kindling induced by chemoconvulsants . Our study appears to be the first to demonstrate that JNK is hyperactivated in chronic epilepsy, and that its pharmacological inhibition reduces spontaneous seizure frequency. This demonstration in the pilocarpine model serves as a rigorous validation of the effects of MAPK modulation on convulsive seizures; since this model replicates complex partial and secondarily generalized seizures seen in humans with TLE, along with hippocampal neurodegeneration typical of mesial temporal sclerosis, these results may have relevance to human epilepsy. It is increasingly recognized that the use of animal models with clear similarities to human epilepsy may aid in the discovery of novel antiepileptic drugs, a pressing clinical need given the lack of progress over recent decades in the medical treatment of refractory epilepsy (Loscher, 2002; Grabenstatter et al., 2005; Loscher and Schmidt, 2011) .
Our evidence for an antiepileptic action aside, the role of JNK activation in promoting neurodegeneration is its most well-established action on neuronal pathophysiology. Impending neuronal death following either kainate administration or kindling is associated with JNK activation (Schauwecker, 2000; Cole-Edwards et al., 2006) . Both genetic deletion of JNK isoforms and pharmacological inhibition of JNK activity protect against excitotoxic neuronal loss from kainate or kindling (Yang et al., 1997; Chen et al., 2010; Spigolon et al., 2010) . JNK activation has also been widely implicated in neurodegeneration acutely following ischemic insults (Borsello et al., 2003; Repici et al., 2007) . Interestingly, chronic JNK hyperactivation has been shown in a variety of neurodegenerative disorders characterized by progressive neuronal loss, including Parkinson's and Alzheimer's diseases (Mehan et al., 2011; Ploia et al., 2011; Wang et al., 2012; Zhou et al., 2015) , but thus far has not been studied in human epilepsy.
Inhibition of p38 MAPK is proconvulsant
We began this project to investigate whether modulation of MAPK signaling could affect seizure frequency in chronically epileptic animals. We had previously demonstrated that hippocampal p38 MAPK activity was diminished in epileptic animals, and contributed to neuronal hyperexcitability as measured in vitro. Our finding here that p38 MAPK inhibition significantly increases spontaneous seizure frequency validated our initial hypothesis. This adds to a growing literature showing dysregulation of phosphorylation signaling pathways in animal models of acquired epilepsy. The most notable example of this is the mammalian target of rapamycin (mTOR) pathway. Although mTOR is a kinase dysregulated in the genetic disorder tuberous sclerosis (TS), evidence has accumulated that it is also hyperactivated in models of acquired epilepsy (Wong, 2011; Guo et al., 2013) . While mTOR inhibition in TS patients shows antiepileptic efficacy (Krueger et al., 2013) , there is conflicting evidence as to whether mTOR inhibition has antiepileptic efficacy in animal models of acquired epilepsy (Huang et al., 2010; Heng et al., 2013) . It is unlikely however that p38 MAPK will prove a target for AED development, since activation of p38 MAPK might have oncogenic potential (Engelberg, 2004) . This study also suggests that p38 MAPK inhibition-a strategy pursued for some years in rheumatologic drug development-might have proconvulsive consequences. Indeed, clinical development of at least one p38 MAPK inhibitor was stopped due to unspecified CNS toxicity in animals, and subsequent inhibitor development has largely focused on agents that do not penetrate the blood-brain barrier (Dominguez et al., 2005; Chico et al., 2009) . Despite these concerns, JNK inhibition may be a more promising target in refractory epilepsy since JNK activation has a clear pathologic association with neurodegeneration.
Limitations and future avenues for investigation
There are several limitations to the findings of this study, and several areas that may warrant further research. The unexpectedly modest degree of JNK antagonism in vivo with SP600125 suggests that further investigation of drug delivery parameters will be needed to produce more substantial JNK inhibition and to test its potential for a complete antiepileptic effect. An alternative approach might include use of D-JNKI1, a novel peptide that inhibits JNK from binding with its substrates Martin and Arthur, 2012) .
JNK encompasses three isoforms, with JNK3 highly implicated in CNS neurodegeneration. We did not separately quantify the expression of these isoforms in our epileptic animals; however, SP inhibits all JNK isoforms, and no subtype-specific antagonists are currently available, thus we cannot pharmacologically test whether the antiepileptic action of JNK inhibition is isoform-dependent.
Finally, despite the clear involvement of JNK activation in neurodegeneration, it is unclear how JNK activation exerts a proconvulsant effect. Several investigations have pointed to a role for JNK activity in neuronal plasticity under nonepileptic, physiological conditions (Haeusgen et al., 2009; Sherrin et al., 2011) , but there is little understanding on how JNK influences the intrinsic and synaptic excitability of neurons. Although p38 MAPK is a strong modulator of HCN channels, which in turn affect neuronal excitability and seizure threshold, JNK does not appear to regulate HCN channels, at least under normal conditions (Poolos et al., 2006) . Nor is it clear whether JNK hyperactivation is a feature of other animal models of epilepsy or of human epilepsy. These are avenues for further investigation to better understand whether modulation of JNK activity might have clinical potential in refractory epilepsy syndromes.
CONCLUSIONS
In this study we have demonstrated for the first time that in vivo pharmacological inhibition of c-Jun N-terminal kinase activity exerts an antiepileptic action, and that JNK is hyperactivated in chronic epilepsy. We also showed that inhibition of p38 MAPK is proconvulsive, in line with our prior results that showed p38 MAPK inhibition increases neuronal excitability when measured in vitro. These findings support the idea that JNK activity may be contributing to maintenance of the epileptic state, and that JNK may be a target for future development of novel antiepileptic therapies.
